Analysts expect Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) to report $4.43 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Dicerna Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $350,000.00 and the highest estimate coming in at $10.00 million. Dicerna Pharmaceuticals reported sales of $130,000.00 during the same quarter last year, which indicates a positive year over year growth rate of 3,307.7%. The firm is scheduled to announce its next earnings report on Thursday, March 29th.
According to Zacks, analysts expect that Dicerna Pharmaceuticals will report full-year sales of $4.43 million for the current fiscal year, with estimates ranging from $500,000.00 to $10.90 million. For the next financial year, analysts anticipate that the firm will report sales of $8.83 million per share, with estimates ranging from $4.50 million to $12.00 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Dicerna Pharmaceuticals.
DRNA has been the subject of a number of analyst reports. SunTrust Banks initiated coverage on Dicerna Pharmaceuticals in a report on Monday, February 5th. They set a “buy” rating and a $13.00 target price for the company. BidaskClub upgraded Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, January 25th. HC Wainwright restated a “buy” rating and set a $10.00 target price (up previously from $6.00) on shares of Dicerna Pharmaceuticals in a report on Friday, November 3rd. ValuEngine upgraded Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. Finally, Zacks Investment Research lowered Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, November 7th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. Dicerna Pharmaceuticals presently has an average rating of “Buy” and an average target price of $10.05.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. RTW Investments LP increased its position in shares of Dicerna Pharmaceuticals by 142.2% in the 4th quarter. RTW Investments LP now owns 5,035,662 shares of the biopharmaceutical company’s stock valued at $44,142,000 after acquiring an additional 2,956,671 shares during the period. Bridger Management LLC acquired a new position in shares of Dicerna Pharmaceuticals in the 4th quarter valued at $8,181,000. Renaissance Technologies LLC increased its position in shares of Dicerna Pharmaceuticals by 19.3% in the 4th quarter. Renaissance Technologies LLC now owns 560,300 shares of the biopharmaceutical company’s stock valued at $5,060,000 after acquiring an additional 90,700 shares during the period. First Manhattan Co. acquired a new position in shares of Dicerna Pharmaceuticals in the 4th quarter valued at $3,865,000. Finally, Vanguard Group Inc. increased its position in shares of Dicerna Pharmaceuticals by 4.5% in the 2nd quarter. Vanguard Group Inc. now owns 340,327 shares of the biopharmaceutical company’s stock valued at $1,078,000 after acquiring an additional 14,517 shares during the period. 24.60% of the stock is currently owned by hedge funds and other institutional investors.
Dicerna Pharmaceuticals (DRNA) traded down $0.30 during trading on Monday, reaching $12.76. The company’s stock had a trading volume of 375,000 shares, compared to its average volume of 428,720. The stock has a market capitalization of $674.43, a price-to-earnings ratio of -3.72 and a beta of 2.75. Dicerna Pharmaceuticals has a one year low of $2.52 and a one year high of $13.92.
Dicerna Pharmaceuticals Company Profile
Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.